Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 7, 2006, Pages 823-828

  Schleyer, V ^a   Radakovic Fijan, S ^b   Karrer, S ^a   Zwingers, T ^c   Tanew, A ^b   Landthaler, M ^a   Szeimies, Rolf Markus ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Fa Estimate GmbH Augsburg   (Germany)

Author keywords

ALA PDT; Clinical trial; Inflammatory disease; Visible light

Indexed keywords

AMINOLEVULINIC ACID; ANTIPSORIASIS AGENT; CORTICOSTEROID; DITHRANOL; VITAMIN D DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPIGMENTATION; MALE; PAIN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, TOPICAL; ADULT; AMINOLEVULINIC ACID; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PSORIASIS; RADIOTHERAPY DOSAGE;

EID: 33746376323     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01651.x     Document Type: Article

References (27)

1. Ortonne JP. Aetiology and pathogenesis of psoriasis. Br J Dermatol 1996; 135: 1-5.
2. Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Derm Venereol 2005; 19: 1-20.
3. Boehncke WH, König K, Kaufmann R et al. Photodynamic therapy in psoriasis: Suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch Dermatol Res 1994; 286: 300-303.
4. Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Rad Biol Med 2000; 28: 537-548.
5. Abels C, Heil P, Dellian M et al. In vivo kinetics and spectra of 5-aminolaevulinic acid-induced fluorescence in an amelanotic melanoma of the hamster. Br J Cancer 1994; 70: 826-833.
6. Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 1994; 343: 801.
7. Collins P, Robinson DJ, Stringer MR. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997; 137: 743-749.
8. Robinson DJ, Collins P, Stringer MR et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 1999; 79: 451-455.
9. Dawe RS, Cameron H, Yule S et al. UV-B phototherapy clears psoriasis through local effects. Arch Dermatol 2002; 138: 1071-1076.
10. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol 1992; B11: 275-292.
11. Kwon HT. Photodynamic therapy with 5-aminolevulinic acid: Protoporphyrin IX production in proliferating lymphoid cells. Student abstracts, University of California, Irvine, 1997. Available online at: http://www.urop.uci.edu/curs/ablist4.html#k.
12. Lui H, Anderson RR. Photodynamic therapy in dermatology. Arch Dermatol 1992; 128: 1631-1636.
13. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002; 146: 178-188.
14. Raghunath M, Beissert S, Schwarz T. Successful photodynamic treatment of chronic psoriatic plaques refractory to conventional therapy. Z Hautkr 2000; 75: 134-136.
15. Hürlimann AF, Panizzon RA, Burg G. Topical photodynamic treatment of skin tumors and dermatoses. Dermatology 1994; 3: 327.
16. Stringer MR, Collins P, Robinson DJ et al. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolaevulinic acid indicates a potential for superficial photodynamic therapy. J Invest Dermatol 1996; 107: 76-81.
17. Fritsch C, Lehmann P, Stahl W et al. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Br J Cancer 1999; 79: 1603-1608.
18. Bissonnette R, Zeng H, McLean DI et al. Psoriatic plaques exhibit red autofluorescence that is due to protoporphyrin IX. J Invest Dermatol 1998; 111: 586-591.
19. Maari C, Viau G, Bissonnette R. Repeated exposure to blue light does not improve psoriasis. J Am Acad Dermatol 2003; 49: 55-58.
20. Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V et al. Topical aminolaevulinic acid based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol 2005; 152: 279-283.
21. Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clin Exp Dermatol 2004; 29: 560-562.
22. Itoh Y, Ninomiya Y, Tajima S et al. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001; 144: 575-579.
23. Exadaktylou D, Kurwa HA, Calonje E et al. Treatment of Darier's disease with photodynamic therapy. Br J Dermatol 2003; 149: 606-610.
24. Kirby B, Whitehurst C, Moore YJ et al. Treatment of lichen planus of the penis with photodynamic therapy. Br J Dermatol 1999; 141: 765-766.
25. Berns MW, Rettenmaier M, McCullough J et al. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative. Lasers Surg Med 1984; 4: 73-77.
26. Bissonnette R, Zeng H, McLean DI et al. Oral aminolevulinic acid induced protoporphyrin IX fluorescence in psoriatic plaques and peripheral blood cells. Photochem Photobiol 2001; 74: 339-345.
27. Boehncke WH, Elshorst-Schmidt T. Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol 2000; 136: 271.